Researchers Identified New Trajectories for Diabetes
A large study characterized diabetes in patients with mitochondrial disease to help guide future care strategies.
Updated on Oct. 13, 2026 in Diabetes
Researchers recently analyzed the GENOMIT registry, which tracked data from 2,300 patients with mitochondrial diseases between July 2009 and January 2025. The study identified specific clinical and genetic trajectories for the 281 patients who developed mitochondrial diabetes mellitus.
Why it matters
By identifying specific risk factors and common therapeutic patterns, researchers aim to move toward more targeted management strategies. This helps clinicians better anticipate the progression of diabetes in patients already diagnosed with mitochondrial disease.
This retrospective registry analysis evaluated 2,300 patients over 15 years to identify genotype-specific patterns for mitochondrial diabetes. Researchers found the m.3243A>G genotype present in 49% of diabetes cases, with a median onset age of 47.7 years.
The players
GENOMIT
An international clinical registry focused on the collection of data from patients with primary mitochondrial diseases.
The details
The study utilized data from the GENOMIT registry across Germany, Austria, and Italy to examine how specific genetic mutations influence metabolic health. Researchers employed a Cox model to assess the impact of body mass index on the development of the condition. Patients with the m.3243A>G genotype were found to be at elevated risk for complications, including polyneuropathy, retinopathy, nephropathy, and hypertension, often requiring insulin therapy as their primary treatment.
Timeline
July 2009 to January 2025: Data collection period for the GENOMIT registry study.
Health Landscape
This research expands the known genetic spectrum of mitochondrial diabetes by utilizing the vast, multi-site data housed in the GENOMIT registry. It establishes a baseline for future genotype-informed investigations into metabolic management for this population.
If you live with a primary mitochondrial disease, this study suggests an average interval of 8.5 years from diagnosis to the potential onset of diabetes. Discussing regular screening for nephropathy and retinopathy with your specialist is a proactive step for long-term health.
The takeaway
Understanding your specific genetic markers can help you and your physician anticipate metabolic changes before they occur. Maintain a consistent screening schedule for hypertension and neuropathy if you have been diagnosed with a mitochondrial disorder.
Further reading
For more on managing metabolic conditions, visit Diabetes.
Source note: This article includes information reported by Endocrinology Advisor.
